NCT05536726View on ClinicalTrials.gov

A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

458

Participants

Timeline

Start Date

January 7, 2023

Primary Completion Date

October 20, 2023

Study Completion Date

June 4, 2024

Conditions
Psoriasis
Interventions
DRUG

608 Q2W

608 160 mg at week 0 + 80 mg Q2W ( 6 cycles) +80 mg Q4W during maintenance period

DRUG

608 Q4W

608 160 mg Q4W ( 3 cycles) +160 mg Q8W during maintenance period

DRUG

Placebo

Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.

Trial Locations (1)

200040

Shanghai Huanshan Hospital Fudan University, Shanghai

All Listed Sponsors
lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY